IL155073A0 - Split enveloped virus preparation - Google Patents
Split enveloped virus preparationInfo
- Publication number
- IL155073A0 IL155073A0 IL15507301A IL15507301A IL155073A0 IL 155073 A0 IL155073 A0 IL 155073A0 IL 15507301 A IL15507301 A IL 15507301A IL 15507301 A IL15507301 A IL 15507301A IL 155073 A0 IL155073 A0 IL 155073A0
- Authority
- IL
- Israel
- Prior art keywords
- enveloped virus
- virus preparation
- split enveloped
- split
- preparation
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18563—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18661—Methods of inactivation or attenuation
- C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0024088A GB0024088D0 (en) | 2000-10-02 | 2000-10-02 | Novel compounds |
| GB0109288A GB0109288D0 (en) | 2001-04-12 | 2001-04-12 | Novel compounds |
| PCT/EP2001/011328 WO2002028426A1 (en) | 2000-10-02 | 2001-10-01 | Split enveloped virus preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155073A0 true IL155073A0 (en) | 2003-10-31 |
Family
ID=26245086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15507301A IL155073A0 (en) | 2000-10-02 | 2001-10-01 | Split enveloped virus preparation |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040028698A1 (es) |
| EP (1) | EP1322329A1 (es) |
| JP (1) | JP2004510747A (es) |
| KR (1) | KR20030055275A (es) |
| CN (1) | CN1253207C (es) |
| AR (1) | AR030829A1 (es) |
| AU (2) | AU2002215914B2 (es) |
| BR (1) | BR0114392A (es) |
| CA (1) | CA2423610A1 (es) |
| CZ (1) | CZ2003930A3 (es) |
| HU (1) | HUP0302636A3 (es) |
| IL (1) | IL155073A0 (es) |
| MX (1) | MXPA03002890A (es) |
| NO (1) | NO20031484L (es) |
| NZ (1) | NZ525076A (es) |
| PL (1) | PL362964A1 (es) |
| WO (1) | WO2002028426A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2244946C (en) * | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| NZ525076A (en) * | 2000-10-02 | 2004-09-24 | Glaxosmithkline Biolog S | A split enveloped RSV virus vaccine fomulation |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
| US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
| CN1305526C (zh) * | 2003-12-29 | 2007-03-21 | 薛平 | 乙型脑炎病毒裂解疫苗及其制备方法 |
| MX2007010306A (es) * | 2005-02-23 | 2007-09-26 | Uab Research Foundation | Vacunacion mejorada con alquil-glicosido. |
| US20090130127A1 (en) | 2005-08-01 | 2009-05-21 | Seiji Tokumoto | Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration |
| ME00045B (me) * | 2006-01-26 | 2010-10-10 | Zoetis Services Llc | Nove kompozicije glikolipidnog adjuvansa |
| GB0622282D0 (en) * | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
| JP5275047B2 (ja) * | 2007-01-31 | 2013-08-28 | 久光製薬株式会社 | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
| RU2531510C2 (ru) | 2008-12-09 | 2014-10-20 | Новавакс, Инк. | Модифицированные f протеины sv и способы их применения |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| US20130236496A1 (en) * | 2010-06-29 | 2013-09-12 | Universite De Laval | Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response |
| PH12013502442A1 (en) * | 2011-05-26 | 2018-03-21 | Glaxo Smithkline Biologicals Sa | Inactivated dengue virus vaccine |
| EP3064218B1 (en) | 2013-10-31 | 2019-06-19 | Hisamitsu Pharmaceutical Co., Inc. | Adjuvant composition |
| KR20160068972A (ko) * | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
| FR3025107B1 (fr) | 2014-08-29 | 2018-10-05 | Calixar | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations |
| KR102667355B1 (ko) | 2015-09-03 | 2024-05-20 | 노바백스, 인코포레이티드 | 개선된 안정성 및 면역원성을 갖는 백신 조성물 |
| ES3028362T3 (en) | 2017-07-24 | 2025-06-19 | Novavax Inc | Methods and compositions for treating respiratory disease |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| EP3768308A4 (en) | 2018-03-19 | 2022-01-26 | Novavax, Inc. | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES |
| EP3775174A4 (en) * | 2018-03-30 | 2022-07-06 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (rsv) vaccines |
| CN110665002B (zh) * | 2019-10-29 | 2023-01-24 | 信阳市动物疫病预防控制中心 | 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法 |
| CN113804593B (zh) * | 2020-06-11 | 2024-05-24 | 北京科兴生物制品有限公司 | 一种裂解疫苗裂解效果的检测方法及应用 |
| EP4175969A4 (en) * | 2020-07-01 | 2024-07-24 | Medimmune, LLC | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT |
| CN112190705A (zh) * | 2020-09-25 | 2021-01-08 | 广州源博医药科技有限公司 | 一种rsv-sh亚单位疫苗及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1486557A (en) * | 1973-10-18 | 1977-09-21 | Flockhart & Co | Process for the preparation of pyrogen-free sub-unit vaccine |
| DE2829089A1 (de) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | Subunit-vakzine |
| DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
| FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| AT405939B (de) * | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
| KR20010042573A (ko) * | 1998-04-09 | 2001-05-25 | 장 스테판느 | 애쥬번트 조성물 |
| US20020004046A1 (en) * | 2000-05-03 | 2002-01-10 | Johnson Leslie S. | Combination therapy of respiratory diseases using antibodies |
| NZ525076A (en) * | 2000-10-02 | 2004-09-24 | Glaxosmithkline Biolog S | A split enveloped RSV virus vaccine fomulation |
-
2001
- 2001-10-01 NZ NZ525076A patent/NZ525076A/en unknown
- 2001-10-01 CZ CZ2003930A patent/CZ2003930A3/cs unknown
- 2001-10-01 US US10/381,486 patent/US20040028698A1/en not_active Abandoned
- 2001-10-01 CA CA002423610A patent/CA2423610A1/en not_active Abandoned
- 2001-10-01 AU AU2002215914A patent/AU2002215914B2/en not_active Ceased
- 2001-10-01 JP JP2002532250A patent/JP2004510747A/ja active Pending
- 2001-10-01 WO PCT/EP2001/011328 patent/WO2002028426A1/en not_active Ceased
- 2001-10-01 BR BR0114392-1A patent/BR0114392A/pt not_active Application Discontinuation
- 2001-10-01 EP EP01986267A patent/EP1322329A1/en not_active Withdrawn
- 2001-10-01 AU AU1591402A patent/AU1591402A/xx active Pending
- 2001-10-01 IL IL15507301A patent/IL155073A0/xx unknown
- 2001-10-01 MX MXPA03002890A patent/MXPA03002890A/es unknown
- 2001-10-01 AR ARP010104630A patent/AR030829A1/es unknown
- 2001-10-01 PL PL01362964A patent/PL362964A1/xx unknown
- 2001-10-01 CN CNB018198090A patent/CN1253207C/zh not_active Expired - Fee Related
- 2001-10-01 KR KR10-2003-7004718A patent/KR20030055275A/ko not_active Ceased
- 2001-10-01 HU HU0302636A patent/HUP0302636A3/hu unknown
-
2003
- 2003-04-01 NO NO20031484A patent/NO20031484L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL362964A1 (en) | 2004-11-02 |
| BR0114392A (pt) | 2003-09-02 |
| NZ525076A (en) | 2004-09-24 |
| AU1591402A (en) | 2002-04-15 |
| WO2002028426A8 (en) | 2002-06-06 |
| US20040028698A1 (en) | 2004-02-12 |
| AU2002215914B2 (en) | 2004-08-19 |
| CZ2003930A3 (cs) | 2003-08-13 |
| NO20031484L (no) | 2003-05-28 |
| CN1477973A (zh) | 2004-02-25 |
| HUP0302636A3 (en) | 2008-03-28 |
| CA2423610A1 (en) | 2002-04-11 |
| NO20031484D0 (no) | 2003-04-01 |
| KR20030055275A (ko) | 2003-07-02 |
| JP2004510747A (ja) | 2004-04-08 |
| MXPA03002890A (es) | 2004-12-03 |
| EP1322329A1 (en) | 2003-07-02 |
| CN1253207C (zh) | 2006-04-26 |
| WO2002028426A1 (en) | 2002-04-11 |
| AR030829A1 (es) | 2003-09-03 |
| HUP0302636A2 (hu) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302636A3 (en) | Split enveloped virus preparation | |
| PL362705A1 (en) | Split enveloped virus preparation for intranasal delivery | |
| GB2337755B (en) | Virus vaccine | |
| GB0020953D0 (en) | Vaccine | |
| HUP0301043A3 (en) | Vaccine | |
| IL150908A0 (en) | Single phase gels and methods for the preparation thereof | |
| AU8189501A (en) | Vaccine composition | |
| HUP0302117A3 (en) | Vaccine composition | |
| GB0020089D0 (en) | Vaccine Composition | |
| AU6269101A (en) | Cosmetic preparation | |
| GB0024200D0 (en) | Component vaccine | |
| GB0017720D0 (en) | Modified virus | |
| GB0014288D0 (en) | Vaccine | |
| GB0001475D0 (en) | Virus strains | |
| GB0014845D0 (en) | Vaccine | |
| GB0026334D0 (en) | Vaccine | |
| AU8252101A (en) | Oct preparations | |
| GB0025694D0 (en) | Vaccine | |
| GB9925432D0 (en) | Virus preparation | |
| GB0003082D0 (en) | Vaccine | |
| GB0006693D0 (en) | Vaccine | |
| GB0015722D0 (en) | Vaccine | |
| GB0027433D0 (en) | Vaccine component | |
| GB9925434D0 (en) | Virus Preparation | |
| GB0015935D0 (en) | Vaccine |